OncoMatch/Clinical Trials/NCT05218889
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Is NCT05218889 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including surufatinib + camrelizumab + nab-paclitaxel + S-1 and nab-paclitaxel + gemcitabine for pancreatic cancer.
Treatment: surufatinib + camrelizumab + nab-paclitaxel + S-1 · nab-paclitaxel + gemcitabine — This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, IV
unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: VEGFR inhibitor
Previously received treatment with VEGFR inhibitors
Cannot have received: immune checkpoint inhibitor
previously used ICI treatment
Cannot have received: systemic anti-tumor treatment
Have received other systemic anti-tumor treatments within 4 weeks prior to enrollment, including chemotherapy, signal transduction inhibitors, hormone therapy, and immunotherapy
Cannot have received: local anti-tumor treatment
Have received local anti-tumor treatments within 4 weeks prior to enrollment, such as hepatic arterial interventional embolism, cryoablation or radiofrequency ablation of metastases to liver
Cannot have received: brachytherapy
Brachytherapy (radioactive seed implantation) within 60 days prior to enrollment
Cannot have received: major surgery
Undergone major surgery within 60 days prior to enrollment or the surgical incision has not completely healed
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥100×10^9/L; Haemoglobin ≥90 g/L
Kidney function
Serum creatinine < 1.5 × ULN; Endogenous creatinine clearance ≥50 mL/min
Liver function
Total bilirubin < 1.5 × ULN; ALT and/or AST < 1.5 × ULN (< 3 × ULN for patients with metastases to liver)
Cardiac function
LVEF (left ventricular ejection fraction) <50% excluded; NYHA classification > Class II excluded; acute myocardial infarction within 6 months, severe/unstable angina, coronary artery bypass surgery, ventricular arrhythmia requiring drug therapy, cardiac failure congestive
The functions of vital organs meet the following requirements... (see above for details); Clinically significant cardiovascular disorders, including but not limited to acute myocardial infarction within 6 months prior to enrollment, severe/unstable angina pectoris, or coronary artery bypass surgery; cardiac failure congestive with NYHA classification > Class II; ventricular arrhythmia requiring drug therapy; LVEF (left ventricular ejection fraction) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05218889 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages